Key Highlights

● BioNTech rose firmly on Friday, trading at about $92.44 in the afternoon, with no new company announcement.

● A media report said the NIH plans a public-private initiative, starting in December, to fast-track cancer-vaccine research.

● BioNTech was founded to develop individualized cancer immunotherapies and developed its Covid-19 Vaccine with Pfizer.

● Moderna jumped $28.00 to $225.00 while Novavax, Vaxcyte and Arcturus rallied, as did Pfizer, Merck and Gilead.

BioNTech (NASDAQ:BNTX) rose firmly on Friday, trading at about $92.44 in the afternoon as messenger RNA, or mRNA, stocks rallied together. The German biotech's American depositary shares moved without any new company announcement. The move followed a media report that the National Institutes of Health plans a public-private initiative, starting in December, to fast-track cancer-vaccine research.

According to the report, the effort would initially target pancreatic, liver and colorectal cancers plus some childhood tumors, and aims to replicate the success of the Covid-19 vaccine program.

For BioNTech, that theme is close to home. The company was founded to develop individualized cancer immunotherapies, including mRNA-based treatments designed to train the immune system to recognize tumors. It became a household name through the Covid-19 vaccine it developed with Pfizer (NYSE:PFE), but oncology has remained at the center of its long-term strategy.

The mRNA trade comes back to life

Friday's rally was broad. Moderna (NASDAQ:MRNA), BioNTech's main mRNA rival, jumped $28.00 to close at $225.00, its highest level since 2021, on the same day it officially entered the Nasdaq-100. Novavax (NASDAQ:NVAX) soared, Vaxcyte (NASDAQ:PCVX) climbed and Arcturus Therapeutics (NASDAQ:ARCT) gained after Leerink Partners raised its price target to $19 from $13. Pfizer, BioNTech's Covid vaccine partner, also rose, as did Merck (NYSE:MRK) and Gilead Sciences (NASDAQ:GILD).

Smaller cancer-focused and genomics names joined in, including ImmunityBio (NASDAQ:IBRX), Twist Bioscience (NASDAQ:TWST) and 10x Genomics (NASDAQ:TXG). Health care was among the S&P 500's leading sectors on the day and for the week.

Caution amid the excitement

The rally rests on a report about a plan, not on new clinical data. Details about which companies might take part in the NIH-linked initiative, how it would be funded and how long any trials might take have not been made public. Cancer vaccines are also notoriously difficult to develop, and many past candidates across the industry have failed in clinical trials.

Still, the report reminded investors that mRNA technology could have uses far beyond Covid-19, a narrative that has been under pressure as Demand for Pandemic vaccines declined. For companies like BioNTech, a high-profile public push into cancer vaccines could raise the profile of their oncology pipelines.

Wider market

Stocks rose broadly. The Nasdaq Composite added 172.83 points to 27,366.17, the S&P 500 gained 46.18 points to 7,811.54, just shy of Tuesday's record close, and the Dow climbed 423.31 points to 51,654.95. Global markets were firm too, with many European indexes closing higher and emerging-market stocks gaining.

The macro picture remained mixed. The 10-year Treasury Yield held near a 24-year high, the Fed raised rates in September for the first time since 2023, and Fed Governor Christopher Waller said Thursday he anticipates additional hikes to bring Inflation back to the Fed's goal. The University of Michigan's preliminary October consumer sentiment index fell to 46.3, a five-month low. Jim Reid, a strategist at Deutsche Bank (NYSE:DB), noted that "we've now entered what has historically been a much stronger seasonal period".

NIH Confirmation and mRNA Developers' Comments on Participation Are the Next Items to Watch

Monday, October 12 is Columbus Day, with stocks open and the Bond Market closed. September consumer prices arrive Wednesday, October 14, followed by producer prices and retail sales on Thursday. Bank Earnings run from October 13 to 16, and the Fed meets on October 27 and 28. Any comment from mRNA developers about taking part in the NIH-linked initiative, and official confirmation ahead of its expected December start, are the next markers for BioNTech.